A vaccine containing recombinant genetically inactivated pertussis PT (PTgen) and filamentous hemagglutinin (FHA) alone (aP5gen) or combined with tetanus and reduced-dose diphtheria toxoids (TdaP5gen) was developed and licensed for immunization of individuals aged 11 years and older in Thailand and in Singapore. The gene discussed is F2; the disease is tetanus.